3+ day, 37+ min ago   (478+ words) ALK rearrangements are uncommon but actionable oncogenic drivers in non–small cell lung cancer. A repeat chest CT on May 8, 2022, showed improvement in pulmonary findings, and a brain MRI performed on the same day showed stable intracranial disease without worsening....

3+ day, 5+ hour ago   (207+ words) Aditya Bardia, MD, MPH, FASCO; Priya Kumar, MBBS, MS Aditya Bardia, MD, MPH, FASCO; Mohammad F. Ali, MD Jonathan Goldman, MD; Sanja Dacic, MD, PhD; Deborah Doroshow, MD, PhD; Anne S. Tsao, MD, MBA Kamel Abou Hussein, MD; Kate Baxstrom, MD Geoffrey…...

4+ day, 1+ min ago   (430+ words) The first patient has been dosed in a phase 2 trial evaluating paxalisib plus gemcitabine in children and young adults with recurrent atypical teratoid/rhabdoid tumor. Across all arms, patients are required to have recurrent or progressive AT/RT; have confirmation…...

4+ day, 3+ hour ago   (452+ words) Data from the phase 3 DeLLphi-305 trial also showed meaningful improvements in progression-free survival and responses with durvalumab/tarlatamab in SCLC. The trial enrolled patients who had not progressed following standard induction treatment with durvalumab plus platinum-based chemotherapy and etoposide. Developers…...

4+ day, 9+ hour ago   (420+ words) Interim phase 2 data show INBRX-106 plus pembrolizumab nearly doubled response rates and extended survival vs pembrolizumab alone in head and neck cancer. The combination of INBRX-106 and pembrolizumab was described as generally manageable. The most common treatment-related adverse effects were…...

4+ day, 5+ hour ago   (245+ words) The faculty discuss treatment selection for a fit patient with relapsed/refractory multiple myeloma (R/R MM) who is eligible for both CAR-T cell therapy and BCMA bispecific antibodies and has access to a certified CAR-T treatment center. Aditya Bardia, MD,…...

4+ day, 21+ hour ago   (347+ words) The FDA withdrew accelerated approval for adagrasib/cetuximab in KRAS G12C-mutated colorectal cancer after the KRYSTAL-10 trial failed to improve survival. Among all treated patients, grade 3 or higher treatment-related adverse effects occurred in 46% of patients who received adagrasib plus cetuximab…...

5+ day, 4+ hour ago   (483+ words) Data from the phase 2 PARADIGM trial may support the use of less toxic, more gentle therapies for patients with acute myeloid leukemia. Azacitidine (Vidaza) plus venetoclax (Venclexta) led to significantly longer event-free survival (EFS) than induction chemotherapy among patients with…...

1+ week, 4+ day ago   (224+ words) Matteo S. Carlino, MD, PhD, FRACP, discusses V940 plus pembrolizumab data, safety, and administration in resected melanoma. The main thing is we’re all excited to see the data available publicly later this year, and hope to see this treatment translate and become…...

1+ week, 4+ day ago   (214+ words) The final FACE-OFF debate examines whether BCMA bispecific antibodies will retain a meaningful role in the management of relapsed/refractory multiple myeloma (R/R MM) as these therapies continue to move into earlier lines of treatment. Kamel Abou Hussein, MD; Yelda…...